Research & Development
Fresenius Kabi's Levothyroxine Sodium Injection Solution launched in US
10 July 2019 -

Germany-based Fresenius Kabi has launched its Levothyroxine Sodium Injection Solution in 100mcg per 5mL, 200mcg per 5mL and 500mcg per 5mL single-dose vials in the United States, it was reported yesterday.

L-thyroxine (T4) is indicated for the treatment of myxoedema coma in adult patients. The product is the first-and-only FDA-approved solution formulation in the United States.

The company also sells Levothyroxine Sodium for Injection as a lyophilised powder in 100mcg, 200mcg and 500mcg per 5mL vial presentations.



Related Headlines